83.58
price down icon4.25%   -3.71
after-market Dopo l'orario di chiusura: 83.58
loading
Precedente Chiudi:
$87.29
Aprire:
$83.175
Volume 24 ore:
5.59M
Relative Volume:
1.45
Capitalizzazione di mercato:
$33.26B
Reddito:
$4.15B
Utile/perdita netta:
$535.20M
Rapporto P/E:
62.37
EPS:
1.34
Flusso di cassa netto:
$575.20M
1 W Prestazione:
-4.56%
1M Prestazione:
-2.59%
6M Prestazione:
+7.47%
1 anno Prestazione:
-25.49%
Intervallo 1D:
Value
$82.75
$85.62
Intervallo di 1 settimana:
Value
$82.75
$87.75
Portata 52W:
Value
$57.52
$117.19

Dexcom Inc Stock (DXCM) Company Profile

Name
Nome
Dexcom Inc
Name
Telefono
(858) 200-0200
Name
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Name
Dipendente
10,300
Name
Cinguettio
@dexcom
Name
Prossima data di guadagno
2024-10-24
Name
Ultimi documenti SEC
Name
DXCM's Discussions on Twitter

Confronta DXCM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Medical Devices icon
DXCM
Dexcom Inc
83.58 33.26B 4.15B 535.20M 575.20M 1.34
Medical Devices icon
ABT
Abbott Laboratories
136.26 233.36B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
104.78 147.06B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
396.74 145.64B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
88.75 112.76B 33.54B 4.66B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
77.18 44.46B 5.54B 4.18B 623.10M 7.00

Dexcom Inc Stock (DXCM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-16 Iniziato Truist Buy
2025-05-30 Iniziato Goldman Buy
2025-04-10 Iniziato Mizuho Outperform
2025-02-03 Aggiornamento Redburn Atlantic Neutral → Buy
2025-01-16 Aggiornamento Robert W. Baird Neutral → Outperform
2024-07-26 Downgrade JP Morgan Overweight → Neutral
2024-07-26 Downgrade Robert W. Baird Outperform → Neutral
2024-05-30 Iniziato Redburn Atlantic Neutral
2024-03-12 Iniziato RBC Capital Mkts Outperform
2023-05-30 Ripresa Morgan Stanley Equal-Weight
2023-04-17 Aggiornamento Raymond James Outperform → Strong Buy
2023-03-29 Iniziato UBS Buy
2023-01-26 Iniziato Wolfe Research Outperform
2022-10-18 Iniziato Barclays Equal Weight
2022-10-12 Iniziato Jefferies Buy
2022-07-15 Iniziato Bernstein Outperform
2022-03-02 Ripresa BofA Securities Buy
2022-02-03 Aggiornamento BTIG Research Neutral → Buy
2022-01-19 Aggiornamento Wells Fargo Equal Weight → Overweight
2022-01-07 Aggiornamento Guggenheim Neutral → Buy
2021-10-18 Downgrade Guggenheim Buy → Neutral
2021-07-21 Ripresa Cowen Outperform
2021-05-28 Aggiornamento Wells Fargo Underweight → Equal Weight
2021-05-25 Iniziato Barclays Overweight
2021-04-15 Iniziato Atlantic Equities Overweight
2021-01-06 Aggiornamento UBS Neutral → Buy
2020-10-02 Downgrade Wells Fargo Equal Weight → Underweight
2020-05-27 Reiterato Piper Sandler Overweight
2020-05-14 Iniziato Wells Fargo Equal Weight
2020-03-05 Iniziato Citigroup Buy
2019-11-07 Reiterato Canaccord Genuity Buy
2019-11-07 Aggiornamento Guggenheim Neutral → Buy
2019-10-23 Iniziato Stifel Buy
2018-11-28 Iniziato UBS Neutral
2018-10-19 Aggiornamento Goldman Sell → Neutral
2018-09-12 Aggiornamento Northland Capital Under Perform → Market Perform
2018-08-02 Reiterato Canaccord Genuity Buy
2018-07-02 Aggiornamento Raymond James Mkt Perform → Outperform
2018-06-08 Aggiornamento JP Morgan Neutral → Overweight
2018-05-11 Iniziato BofA/Merrill Buy
2018-05-03 Reiterato Canaccord Genuity Buy
2018-04-04 Iniziato Goldman Sell
2018-04-04 Iniziato Guggenheim Neutral
2018-03-23 Aggiornamento Robert W. Baird Neutral → Outperform
2018-01-04 Downgrade Northland Capital Market Perform → Under Perform
2017-09-28 Reiterato Wedbush Outperform
Mostra tutto

Dexcom Inc Borsa (DXCM) Ultime notizie

pulisher
Jun 18, 2025

Dexcom EVP Brown sells $41k in shares - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Diabetics at Risk: FDA Issues Highest-Level Recall on 2M Dexcom Devices Over 'Deadly Fault' - inkl

Jun 18, 2025
pulisher
Jun 18, 2025

Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight - GlobeNewswire Inc.

Jun 18, 2025
pulisher
Jun 18, 2025

Dexcom Ireland announce golfer Liam Nolan as a brand ambassador - Galway Advertiser

Jun 18, 2025
pulisher
Jun 18, 2025

Dexcom recalls more than 2 million CGM receivers for lack of audible alarm - MedTech Dive

Jun 18, 2025
pulisher
Jun 18, 2025

Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025 - Dexcom

Jun 18, 2025
pulisher
Jun 18, 2025

Breakthrough Study Reveals Doctors Choose CGM Over Medications as Future of Type 2 Diabetes Treatment - Stock Titan

Jun 18, 2025
pulisher
Jun 17, 2025

Q1 Rundown: DexCom (NASDAQ:DXCM) Vs Other Patient Monitoring Stocks - FinancialContent

Jun 17, 2025
pulisher
Jun 17, 2025

Dexcom Faces TM Suit Over 'Stelo' Glucose Monitor Product - Law360

Jun 17, 2025
pulisher
Jun 17, 2025

Goldman Sachs Initiates Coverage of DexCom (DXCM) With Buy Rating - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

DexCom’s SWOT analysis: CGM leader’s stock poised for growth amid challenges - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

DexCom's SWOT analysis: CGM leader's stock poised for growth amid challenges - Investing.com

Jun 17, 2025
pulisher
Jun 16, 2025

Expert Outlook: DexCom Through The Eyes Of 8 Analysts - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

DexCom Stock: Is DXCM Underperforming the Health Care Sector? - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

DexCom (DXCM) Receives 'Buy' Rating from Truist Securities with $102 Price Target | DXCM Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

DexCom (DXCM) Gains Analysts' Favor Despite Past Challenges - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

DexCom Stock: Is DXCM Underperforming The Health Care Sector? - Barchart.com

Jun 16, 2025
pulisher
Jun 16, 2025

DexCom (DXCM) Receives Buy Rating Amid Promising Market Prospects | DXCM Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Truist Initiates DexCom at Buy With $102 Price Target - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

DexCom Insiders Sell US$11m Of Stock, Possibly Signalling Caution - simplywall.st

Jun 16, 2025
pulisher
Jun 10, 2025

Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - Business Wire

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7 - MassDevice

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet Releases Omnipod 5 App for iPhone with Dexcom G7 CGM in U.S. - Medical Product Outsourcing

Jun 10, 2025
pulisher
Jun 10, 2025

Diabetes partnerships abound ahead of ADA - BioWorld MedTech

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet's Omnipod® 5 App For iPhone With Dexcom G7 Integration Now Available To All US Users - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet (PODD) Omnipod 5 App Now Compatible with Dexcom G7 on iPhone | PODD Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users | PODD Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users - Business Wire

Jun 10, 2025
pulisher
Jun 09, 2025

DexCom, Inc. (DXCM) Stock Analysis: Analyst Consensus Points to 13.59% Potential Upside - DirectorsTalk Interviews

Jun 09, 2025
pulisher
Jun 08, 2025

DexCom (NASDAQ:DXCM) Stock Rating Upgraded by Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire

Jun 05, 2025
pulisher
Jun 04, 2025

BGM and CGM Market is Set to Experience a Revolutionary Growth | Abbott Laboratories , Dexcom, Medtronic PLC - openPR.com

Jun 04, 2025
pulisher
Jun 02, 2025

Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Should You Be Excited About DexCom, Inc.'s (NASDAQ:DXCM) 24% Return On Equity? - simplywall.st

Jun 02, 2025
pulisher
Jun 01, 2025

Goldman Sachs Initiates Coverage of DexCom (XTRA:DC4) with Buy Recommendation - Nasdaq

Jun 01, 2025
pulisher
May 31, 2025

Goldman Sachs Initiates Coverage of DexCom (BIT:1DXCM) with Buy Recommendation - Nasdaq

May 31, 2025
pulisher
May 31, 2025

DexCom (NASDAQ:DXCM) Now Covered by Analysts at The Goldman Sachs Group - Defense World

May 31, 2025
pulisher
May 30, 2025

Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation - Nasdaq

May 30, 2025
pulisher
May 30, 2025

Forecasting The Future: 7 Analyst Projections For DexCom - Benzinga

May 30, 2025
pulisher
May 30, 2025

DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Call Transcript - MSN

May 30, 2025
pulisher
May 30, 2025

Jefferies Adjusts Price Target on DexCom to $110 From $105, Maintains Buy Rating - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Goldman Sachs Initiates DexCom at Buy With $104 Price Target - marketscreener.com

May 30, 2025
pulisher
May 29, 2025

DexCom (DXCM) Receives Positive Coverage with Growth Potential | - GuruFocus

May 29, 2025
pulisher
May 29, 2025

DexCom (DXCM) Receives Positive Coverage with Growth Potential | DXCM Stock News - GuruFocus

May 29, 2025
pulisher
May 28, 2025

Dexcom’s EVP Sadie Stern sells $526,318 in shares - Investing.com

May 28, 2025
pulisher
May 27, 2025

GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - The Globe and Mail

May 27, 2025
pulisher
May 26, 2025

DexCom, Inc. (DXCM) Stock Analysis: 15.97% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews

May 26, 2025
pulisher
May 24, 2025

DexCom’s SWOT analysis: CGM leader faces supply challenges amid growth - Investing.com

May 24, 2025
pulisher
May 23, 2025

DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move? - Smartkarma

May 23, 2025

Dexcom Inc Azioni (DXCM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Dexcom Inc Azioni (DXCM) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
FOLETTA MARK G
Director
Jun 16 '25
Sale
83.13
2,750
228,605
56,621
Brown Michael Jon
EVP, Chief Legal Officer
Jun 16 '25
Sale
82.80
500
41,400
95,102
AUGUSTINOS NICHOLAS
Director
Jun 16 '25
Sale
82.80
3,672
304,042
33,411
AUGUSTINOS NICHOLAS
Director
Jun 13 '25
Sale
81.69
2,618
213,864
37,083
$75.95
price up icon 2.54%
medical_devices STE
$242.66
price up icon 1.02%
medical_devices EW
$77.18
price down icon 1.32%
medical_devices PHG
$24.20
price up icon 0.92%
$299.99
price down icon 4.52%
Capitalizzazione:     |  Volume (24 ore):